EISAI CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,824 JPY | -1.36% |
|
-2.43% | -17.41% |
| Apr. 01 | Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment | MT |
| Apr. 01 | BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug | MT |
| Sales 2024 * | 735B 4.76B | Sales 2025 * | 778B 5.04B | Capitalization | 1,693B 10.97B |
|---|---|---|---|---|---|
| Net income 2024 * | 41.04B 266M | Net income 2025 * | 49.99B 324M | EV / Sales 2024 * | 2.07 x |
| Net cash position 2024 * | 172B 1.12B | Net cash position 2025 * | 184B 1.19B | EV / Sales 2025 * | 1.94 x |
| P/E ratio 2024 * |
41.5
x | P/E ratio 2025 * |
34
x | Employees | 11,076 |
| Yield 2024 * |
2.75% | Yield 2025 * |
2.81% | Free-Float | 93.84% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eisai Co., Ltd.
More recommendations
More press releases
| 1 day | -1.36% | ||
| 1 week | -2.43% | ||
| Current month | -6.31% | ||
| 1 month | -9.66% | ||
| 3 months | -17.74% | ||
| 6 months | -30.58% | ||
| Current year | -17.41% |
1 week
5 811.00
6 052.00
1 month
5 811.006 441.00
Current year
5 811.007 818.00
1 year
5 811.0011 250.00
3 years
5 011.0012 765.00
5 years
5 011.0012 765.00
10 years
3 878.0012 765.00
| Managers | Title | Age | Since |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 75-09-30 |
Mitsuru Shomon
DFI | Director of Finance/CFO | - | - |
Makoto Hoketsu
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 75-09-30 |
Fumihiko Ike
BRD | Director/Board Member | 71 | 21-05-31 |
Hideki Hayashi
BRD | Director/Board Member | 66 | 81-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.78% | 15 M€ | +4.35% | ||
| 1.23% | 251 M€ | +13.08% | ||
| 1.13% | 31,732 M€ | +14.80% | - | |
| 1.12% | 1,198 M€ | +13.89% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 5,824 | -1.36% | 1 118 500 |
| 24-04-17 | 5,904 | -2.45% | 1,041,800 |
| 24-04-16 | 6,052 | +0.67% | 797,900 |
| 24-04-15 | 6,012 | -0.48% | 648,000 |
| 24-04-12 | 6,041 | +1.21% | 776,900 |
Delayed Quote Japan Exchange, April 18, 2024 at 02:00 am EDT
More quotes
Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (87.7%): prescribed drugs, health products, etc.;
- other (12.3%): food additives, chemical products, etc.
Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).
Sector
Pharmaceuticals
Calendar
2024-05-14
- Q4 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
5,904
JPY
Average target price
8,193
JPY
Spread / Average Target
+38.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.41% | 10.95B | |
| +28.79% | 676B | |
| +24.17% | 554B | |
| -7.64% | 349B | |
| +15.00% | 318B | |
| +5.99% | 291B | |
| +3.23% | 210B | |
| -0.24% | 204B | |
| -9.78% | 194B | |
| -11.71% | 144B |
- Stock Market
- Equities
- 4523 Stock
